RT Conference Proceedings
T1 Impact of ribociclib (RIB) dose reduction on overall survival (OS) in patients (pts) with HR+/HER2-advanced breast cancer (ABC) in MONALEESA (ML)-3 and-7
A1 De Laurentiis, M.
A1 Merino, L. de la Cruz
A1 Hart, L.
A1 Bardia, A.
A1 Im, S-A.
A1 Sohn, J.
A1 Neven, P.
A1 Martin, M.
A1 Ji, Y.
A1 Yang, S.
A1 Hu, H.
A1 Lteif, A.
A1 Tripathy, D.
PB Elsevier
SN 0923-7534
YR 2020
FD 2020-09-01
LK https://hdl.handle.net/10668/27555
UL https://hdl.handle.net/10668/27555
LA en
DS RISalud
RD Apr 17, 2025